Gilead Sciences to launch more healthcare products in China

California-based biopharmaceutical firm Gilead Sciences Inc is accelerating plans to launch more products in China, as part of its efforts to tap the nation's growing healthcare market.

The company aims to launch three more products in China by the end of this year. Currently, Gilead has two anti-hepatitis C drugs in the market. Then on Saturday, Gilead launched Genvoya, a drug designed for the treatment of HIV-1 infection in adults and children weighing over 35 kilograms and 12 years of age and older. It is also the country's first approved single tablet regimen treatment for HIV-1 infection.

According to a report from qianzhan.com, an industry information provider, Gilead's market share for anti-AIDS products was roughly 90 percent in 2017 in China.